Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 60 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Convalescent COVID 19 Plasma Clear all
Terminated Phase 3 Interventional

Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy

NCT04361253
View directory record Official record
Conditions
COVID, Infectious Disease
Interventions
High-Titer COVID-19 Convalescent Plasma (HT-CCP), Standard Plasma (FFP)
Biological
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
12 Months and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 6, 2026, 10:56 AM EDT
No Longer Available No phase listed Expanded access

Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19

NCT04445207
View directory record Official record
Conditions
COVID, Sars-CoV2, Corona Virus Infection
Interventions
Convalescent Plasma
Biological
Lead sponsor
Jonathan Gerber
Other
Eligibility
12 Years and older
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 6, 2026, 10:56 AM EDT
Completed No phase listed Observational

Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19

NCT04360278
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 6, 2026, 10:56 AM EDT
Terminated Phase 2 Interventional Results available

Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection

NCT04513158
View directory record Official record
Conditions
Covid19
Interventions
Convalescent Plasma
Biological
Lead sponsor
Joseph M. Flynn, D.O., MPH
Other
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 6, 2026, 10:56 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Phase 3 Open-Label Controlled Trial of Convalescent Plasma in Early COVID-19 Infection

NCT06084351
View directory record Official record
Conditions
Covid19
Interventions
Convalescent Plasma, Standard of Care
Drug · Other
Lead sponsor
Larkin Community Hospital
Other
Eligibility
40 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 6, 2026, 10:56 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma

NCT04497779
View directory record Official record
Conditions
Asymptomatic COVID-19 Infection Laboratory-Confirmed, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Biospecimen Collection, Diagnostic Laboratory Biomarker Analysis, Electronic Health Record Review, Questionnaire Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 6, 2026, 10:56 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Convalescent Plasma vs. Standard Plasma for COVID-19

NCT04344535
View directory record Official record
Conditions
COVID
Interventions
Convalescent Plasma, Standard Donor Plasma
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 6, 2026, 10:56 AM EDT
Completed Phase 1 Interventional

Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)

NCT04554992
View directory record Official record
Conditions
Covid19
Interventions
COVID 19 Convalescent Plasma
Biological
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 6, 2026, 10:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection

NCT04392232
View directory record Official record
Conditions
Coronavirus, COVID-19, Convalescent Plasma
Interventions
Convalescent Plasma
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
16 Years and older
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Oct 6, 2026, 10:56 AM EDT
Completed No phase listed Observational

COVID-19 Infection in Patients Receiving Anti-CD20 Therapy

NCT04884477
View directory record Official record
Conditions
COVID-19, Immunosuppressed Host, Convalescent Plasma, Anti-CD20 Therapy
Interventions
Convalescent Plasma
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 6, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Results available

COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.

NCT04397757
View directory record Official record
Conditions
COVID-19
Interventions
COVID-19 Convalescent Plasma
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 6, 2026, 10:56 AM EDT
Terminated Phase 2 Interventional Results available

Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection

NCT04343755
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent Plasma
Biological
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 6, 2026, 10:56 AM EDT
Terminated Phase 2 Interventional Results available

ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)

NCT04432272
View directory record Official record
Conditions
COVID-19, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
Interventions
COVID-19 convalescent plasma
Biological
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 6, 2026, 10:56 AM EDT
Terminated Phase 2 Interventional Results available

Use of Convalescent Plasma for COVID-19

NCT04408040
View directory record Official record
Conditions
COVID
Interventions
Convalescent Plasma
Biological
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 6, 2026, 10:56 AM EDT
Recruiting Phase 2 Interventional

Convalescent Plasma as a Possible Treatment for COVID-19

NCT04442191
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent plasma, Placebo
Biological
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Oct 6, 2026, 10:56 AM EDT
No Longer Available No phase listed Expanded access

Convalescent Plasma for the Treatment of Patients With COVID-19

NCT04372368
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
COVID-19 Convalescent Plasma
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
U.S. locations
6
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 6, 2026, 10:56 AM EDT
Completed Phase 2 Interventional Results available

Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia

NCT04374565
View directory record Official record
Conditions
Corona Virus Infection, SARS-CoV 2, SARS Pneumonia, Pneumonia
Interventions
High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 6, 2026, 10:56 AM EDT
Completed Phase 2 Interventional Results available

Plasma Therapy of COVID-19 in Severely Ill Patients

NCT04359810
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Convalescent Plasma (anti-SARS-CoV-2 plasma), Non-convalescent Plasma (control plasma)
Biological
Lead sponsor
Max O'Donnell
Other
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 6, 2026, 10:56 AM EDT
Completed No phase listed Observational Results available

Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19

NCT04545047
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
COVID-19 convalescent plasma
Biological
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 80 Years
Enrollment
5,044 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 6, 2026, 10:56 AM EDT
Completed Phase 3 Interventional Results available

Convalescent Plasma in Outpatients With COVID-19

NCT04355767
View directory record Official record
Conditions
Covid19
Interventions
Convalescent Plasma, Saline
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
53
States / cities
Chandler, Arizona • Phoenix, Arizona • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 6, 2026, 10:56 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 6, 2026, 10:56 AM EDT
Not listed Phase 1 Interventional

Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions

NCT04462848
View directory record Official record
Conditions
Corona Virus Infection
Interventions
anti-SARS-CoV-2 human convalescent plasma
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
1 Month to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 6, 2026, 10:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Convalescent Plasma to Stem Coronavirus (CSSC-001)

NCT04323800
View directory record Official record
Conditions
Coronavirus, Convalescence
Interventions
Anti- SARS-CoV-2 Plasma, SARS-CoV-2 non-immune Plasma
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
25
States / cities
Birmingham, Alabama • Whiteriver, Arizona • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Oct 6, 2026, 10:56 AM EDT